RU2001122818A - Urea derivatives (options), pharmaceutical composition (options) and method for treating a disease associated with the growth of cancer cells (options) - Google Patents

Claims (67)

1. A compound of general formula ADB (I) or a pharmaceutically acceptable salt thereof, wherein D is —NH — C (O) —NH—, A is a substituted structure containing up to 40 carbon atoms of the formula —L— (M-L ¹ ) _q where L is a 5- or 6-membered cyclic structure linked directly to D, L ¹ contains a substituted cyclic structure having at least 5 members, M is a bridging group having at least one atom, q is an integer from 1 to 3 and each cyclic structure in L and L ¹ contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and is a substituted or unsubstituted aryl to a tricyclic aryl or a heteroaryl group containing up to 30 carbon atoms with at least one 6-membered cyclic structure linked directly to D containing 0-4 members of a group consisting of nitrogen, oxygen and sulfur, wherein L ¹ is substituted with at least one substituent selected from the group consisting of —SO ₂ R _x , —C (O) R _x and —C (NR _y ) R _z , R _y is hydrogen or a carbon-based structure, containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally optionally halogen-substituted up to the formation of a perhaloid compound, R _z is hydrogen or a carbon-based structure containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S, and O, and optionally substituted with halogen, hydroxy, and carbon-based substituents containing up to 24 carbon atoms that optionally contain heteroatoms selected from N, S and O, and optionally substituted with halogen; R _x is R _Z or NR _a R _b , where R _a and R _b , a) are independently represented by hydrogen, a carbon-based structure containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted halogen, hydroxy and carbon-based substituents containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, and are optionally substituted with halogen, or —OSi (R _f ) ₃ , where R _f is hydrogen or a structure carbon based containing up to 24 carbon atoms, optionally with containing heteroatoms selected from N, S, and O, and optionally substituted with halogen, hydroxy, and carbon-based substituents containing up to 24 carbon atoms, which optionally contains heteroatoms selected from N, S, and O, and are optionally substituted with halogen, or b ) R _a and R _b together form a 5-7 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted with halogen, hydroxy or substituents on the main ve carbon containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, optionally substituted with halogen, or c) one of R _a or R _b is -C (O) -, C ₁ -C ₅ a divalent alkylene group or a substituted C ₁ -C ₅ divalent alkylene group bonded to structure L to form a cyclic structure of at least 5 members, in which substituents of a substituted C ₁ -C ₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy group and carbon-based substituents and containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; where B is substituted, L is substituted or L ¹ is further substituted, wherein the substituents are selected from the group consisting of halogen to perhalogen and Wn, where n = 0-3; each W independently selected from the group consisting of —CN, —CO ₂ R ⁷ , —C (O) NR ⁷ R ⁷ , —C (O) —R ⁷ , —NO ₂ , —OR ⁷ , —SR ⁷ , -NR ⁷ R ⁷ , -NR ⁷ C (O) OR ⁷ , -NR ⁷ C (O) R ⁷ , -Q-Ar and carbon-based structures containing up to 24 carbon atoms, optionally containing heteroatoms selected from N , S and O, and optionally substituted with one or more substituents independently selected from the group consisting of —CN, —CO ₂ R ⁷ , —C (O) R ⁷ , —C (O) NR ⁷ R ⁷ , —OR ⁷ , —SR ⁷ , —NR ⁷ R ⁷ , —NO ₂ , —NR ⁷ C (O) R ⁷ , —NR ⁷ C (O) OR ⁷ and halogen up to the formation of a perhaloid compound, with each R ⁷ independently selected from H or carbon based structure genus, containing up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is -O-, -S-, -N (R ⁷⁾ -, - (CH _{2) m} -, -C (O) -, -CH (OH) -, - (CH ₂ ) _m О-, - (CH ₂ ) _m S -, - (CH ₂ ) _m N (R ⁷ ) -, -O (CH ₂ ) _m - CHX ^a -, -CX ^a ₂ , -S- (CH ₂ ) _m - and -N (R ⁷ ) (CH ₂ ) _m -, where m = 1-3, and X ^a represents halogen, and Ar is a 5- or 6-membered aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted with halogen until the formation of a perhaloid compound Ia and neobyazatelnozameschennoy Z _n1, wherein n1 = 0-3 and each Z is independently selected from the group consisting of -CN, -CO ₂ R ^7, -C (O) R ^7, -C (O) NR ⁷ R ^7, - NO ₂ , —OR ⁷ , —SR ⁷ , —NR ⁷ R ⁷ , —NR ⁷ C (O) OR ⁷ , —NR ⁷ C (O) R ^7, and a carbon-based structure containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted with one or more substituents selected from the group consisting of —CN, —CO ₂ R ⁷ , —COR ⁷ , —C (O) NR ⁷ R ⁷ , —OR ⁷ , -SR ⁷ , -NO ₂ , -NR ⁷ R ⁷ , -NR ⁷ C (O) R ⁷ and -NR ⁷ C (O) OR ⁷ , where R ^{7 is} defined above. 2. The compound according to claim 1, characterized in that R _y represents hydrogen, C _1-10 alkyl, C _1-10 alkoxygroup, C _3-10 cycloalkyl containing 0-3 heteroatoms, C _2-10 alkenyl, C _{1 -10} alkenoyl, C _6-12 aryl, C _3-12 heteroaryl containing 1-3 heteroatoms selected from N, S and O, C _7-24 aralkyl, C _7-24 alkaryl, substituted C _1-10 alkyl, substituted C _1-10 alkoxy, substituted C _3-10 cycloalkyl containing 0-3 heteroatoms selected from N, S and O, substituted C ₆ -C ₁₄ aryl, substituted C ₃ -C ₁₂ heteroaryl containing 1-3 heteroatoms, selected of N, S and O, substituted C _7-24 alkaryl or substituted C ₇ -C ₂₄ Aral yl, wherein R _y - substituted group which is substituted by halogen up to the formation perhalogen compounds, R _Z represents hydrogen, hydrogen, C _1-10 alkyl, C _1-10 alkoxy, C _3-10 cycloalkyl having 0-3 heteroatoms, C _2-10 alkenyl, C _1-10 alkenoyl, C _6-12 aryl, C ₃ -C ₁₂ heteroaryl containing 1-3 heteroatoms selected from S, N and O, C _7-24 alkaryl, C _7-24 aralkyl, substituted C _1-10 alkyl, substituted C _1-10 alkoxy, substituted C ₆ -C ₁₄ aryl, substituted C ₃ -C ₁₀ cycloalkyl containing 0-3 heteroatoms selected from S, N and O, substituted C _3-12 heteroaryl containing 1-3 goethe a roatom selected from S, N and O, substituted C _7-24 alkaryl or substituted C ₇ -C ₂₄ aralkyl, where R _Z is a substituted group, and it is substituted with halogen until the formation of a perhaloid compound, hydroxy, C _1-10 alkyl, C _3-12 cycloalkyl containing 0-3 heteroatoms selected from O, S and N, C _3-12 heteroaryl containing 1-3 heteroatoms selected from N, S and O, C _1-10 alkoxy group, C _{6- 12} aryl, C _1-6 halo-substituted alkyl up to the formation perhalogen alkyl, C _6-12 halogen-substituted aryl up to the formation perhalogen aryl, C _3-12 galogenzamesch nnym cycloalkyl up to the formation perhalogen cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted _C3-C12 heteroaryl, up to the formation perhalogen heteroaryl containing 1-3 heteroatoms selected from O, N and S, halo substituted With ₇ -C ₂₄ aralkyl up to the formation of pergaloid aralkyl, a halogen-substituted C ₇ -C ₂₄ alkaryl up to the formation of pergaloid alkaryl and -C (O) R _g , R _a and R _b are a) independently hydrogen, a carbon-based structure, selected from the group consisting of C ₁ -C ₁₀ al kila, C ₁ -C ₁₀ alkoxy groups, C _3-10 cycloalkyl, C _2-10 alkenyl, C _1-10 alkenoyl, C _6-12 aryl, C _3-12 heteroaryl containing 1-3 heteroatoms selected from O, N and S, C _3-12 cycloalkyl containing 0-3 heteroatoms selected from N, S and O, C _7-24 aralkyl, C ₇ -C ₂₄ alkaryl, substituted C _1-10 alkyl, substituted C _1-10 alkoxy groups substituted C _3-10 cycloalkyl containing 0-3 heteroatoms selected from N, S and O; substituted C _6-12 aryl; substituted C _3-12 heteroaryl containing 1-3 heteroatoms selected from N, S and O, substituted C _7-24 aralkyl, substituted C _7-24 alkaryl, where R _a and R _b represented enes substituted group, they are substituted with halogen up to formation perhalogen compounds, hydroxy, C _1-10 alkyl, C _3-13 cycloalkyl having 0-3 heteroatoms selected from O, S and N, C _3-12 heteroaryl comprising 1 -3 heteroatoms selected from N, S and O, C _1-10 alkoxy, C _6-12 aryl, C _1-6 halogen-substituted alkyl until the formation of perhaloid alkyl, C ₆ -C ₁₂ halogen substituted aryl until the formation of perhaloid aryl, C ₃ -C ₁₂ halogen-substituted cycloalkyl containing 0-3 heteroatoms selected from N, S and O, up to the image perhaloid cycloalkyl, a halogen-substituted C ₃ -C ₁₂ heteroaryl until the formation of a pergaloid heteroaryl, a halogen-substituted C ₇ -C ₂₄ aralkyl until the formation of a pergaloid aralkyl, a halogen-substituted C ₇ -C ₂₄ alkaryl until the formation of perhaloid alkaryl R- _g- alkaryl and or -OSi (R _f ) ₃ , where R _f is hydrogen, C _1-10 alkyl, C _1-10 alkoxy, C ₃ -C ₁₀ cycloalkyl containing 0-3 heteroatoms selected from O, S and N, C _6-12 aryl, C ₃ -C ₁₂ heteroaryl containing 1 to 3 heteroatoms selected from O, S and N, C _7-24 aralkyl, substituted C _1-10 alkyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ -C ₁₂ cycloalkyl containing 0-3 heteroatoms selected from O, S and N, substituted C ₃ -C ₁₂ heteroaryl containing 1-3 heteroatoms selected from O, S and N, substituted C _{6- 12} aryl and substituted C _7-24 alkaryl, where R _f is a substituted group, and it is substituted with halogen until the formation of a perhaloid compound, a hydroxy group, C _3-12 alkyl, C _3-12 cycloalkyl containing 0-3 heteroatoms selected from O , S and N, C _3-12 heteroaryl containing 1-3 heteroatoms selected from N, S and O, C _1-10 alkoxy, C _6-12 aryl, C ₇ -C ₂₄ alkaryl, C ₇ -C ₂₄ aralkyl , C _1-6 halogen-substituted alkyl until the formation of perhaloid alkyl, C ₆ -C ₁₂ halogen-substituted aryl until the formation of pergaloid aryl, C ₃ -C ₁₂ halogen-substituted cycloalkyl containing 0-3 heteroatoms selected from N, S and O, up to the formation of perhaloid cycloalkyl, halogen-substituted C ₃ -C ₁₂ heteroaryl until the formation of pergaloid heteroaryl, halogen-substituted C ₇ -C ₂₄ aralkyl until the formation of pergaloid aralkyl, halogen-substituted C ₇ -C ₂₄ alkaryl until the formation of perhaloid alkaryl and -C (O) R _g , or b) R _a and R _b together form a 5-7 membered heterocyclic structure with 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 membered heterocyclic structure with 1-3 heteroatoms selected from N, S and O with substituents selected from the group consisting of halogen up to the formation of a perhaloid compound, a hydroxy group, C _1-10 alkyl, C _3-12 cycloalkyl containing 0-3 heteroatoms selected from O, S and N, C _3-12 heteroaryl containing 1-3 heteroatoms selected from N, S and O, C _1-10 alkoxy, C _6-12 aryl, C ₇ -C ₂₄ alkaryl, C ₇ -C ₂₄ aralkyl, galogenzamesch nnogo C _1-6 alkyl up to the formation perhalogen alkyl, halosubstituted C ₆ -C ₁₂ aryl, up to the formation perhalogen aryl, halosubstituted C ₃ -C ₁₂ cycloalkyl, containing 0-3 heteroatoms selected from N, S and O, up to the formation perhalogen cycloalkyl, halosubstituted C ₃ -C ₁₂ heteroaryl up to the formation perhalogen heteroaryl galogezameschennogo C ₇ -C ₂₄ aralkyl, up to the formation perhalogen aralkyl, halogenated C ₇ -C ₂₄ alkaryl up to the formation perhalogen alkaryl, and -C (O) R _g, or c) odi of R _a or R _b is -C (O) -, C ₁ -C ₅ divalent alkylene group or a substituted C ₁ -C ₅ divalent alkylene group bound to the structure of L to form a cyclic structure of at least 5 members, wherein the substituents in the substituted C ₁ -C ₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy group, C _1-10 alkyl, C _3-12 cycloalkyl containing 0-3 heteroatoms selected from O, S and N, C _{3- 12} heteroaryl containing 1-3 heteroatoms selected from N, S and O, C _1-10 alkoxy, C _6-12 aryl, C ₇ -C ₂₄ alkaryl, C ₇ -C _24, and alkyl, C _1-6 halo-substituted alkyl up to the formation perhalogen alkyl, C ₆ -C ₁₂ halogenated aryl up to the formation perhalogen aryl, C ₃ -C ₁₂ halogenated cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to form perhalogen cycloalkyl, halosubstituted C ₃ -C ₁₂ geterarila until the formation perhalogen geterarila, halogenated C ₇ -C ₂₄ aralkyl, up to the formation perhalogen aralkyl, halogenated C ₇ -C ₂₄ alkaryl, up to the formation perhalogen alka yl and -C (O) R _g, wherein R _g represents a C _1-10 alkyl, -CN, -CO _{2 R d, -OR d, -SR d} , -NO _2, -C (O) R _c, —NR _d R _c , —NR _d C (O) OR _e and —NR _d C (O) R _e , and R _d and R _{e are} independently selected from the group consisting of hydrogen, C _1-10 alkyl, C _{1- 10} alkoxy groups, C _3-10 cycloalkyl containing 0-3 heteroatoms selected from O, N and S, C _6-12 aryl, C ₃ -C ₁₂ heteroaryl with 1-3 heteroatoms selected from O, N and S, and C ₇ -C ₂₄ aralkyl, C ₇ -C ₂₄ alkaryl substituted up to the pergaloid C ₁ -C ₁₀ alkyl, substituted up to the pergaloid C ₃ -C ₁₀ cycloalkyl containing 0-3 heteroatoms selected from O, N and S, substituted up to perg logaloidnogo C ₆ -C ₁₄ aryl substituted with up to perhalogen C ₃ -C ₁₂ heteroaryl containing 1-3 heteroatoms selected from O, N and S, up perhalogen substituted C ₇ -C ₂₄ alkaryl, up to perhalogen substituted C ₇ - With ₂₄ aralkyl, W is independently selected from the group consisting of —CN, —CO ₂ R ⁷ , —C (O) NR ⁷ R ⁷ , —C (O) —R ⁷ , —NO ₂ , —OR ⁷ , - SR ⁷ , —NR ⁷ R ⁷ , —NR ⁷ C (O) OR ⁷ , —NR ⁷ C (O) R ⁷ , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy groups, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkenoyl, C ₃ -C ₁₀ cycloalkyl containing 0-3 heteroatoms selected from O, S and N, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, C ₇ -C ₂₄ aralkyl, C _C3-C12 geteroa sludge containing 1-3 heteroatoms selected from O, N and S, C ₄ -C ₂₃ alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C ₁ -C ₁₀ alkyl, substituted C ₁ -C ₁₀ alkoxy groups, substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkenoyl, substituted C ₃ -C ₁₀ cycloalkyl containing 0-3 heteroatoms selected from O, N and S, substituted C ₆ -C ₁₂ aryl, substituted C ₃ -C ₁₂ heteroaryl containing 1-3 heteroatoms selected from O, N and S, substituted C ₇ -C ₂₄ aralkyl, substituted C ₇ -C ₂₄ alkaryl, substituted C ₄ -C ₂₃ alkheteroaryl containing 1-3 heteroatoms you rannyh from O, N and S, and -Q-Ar; R ⁷ is independently selected from H, C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy groups, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkenoyl, C ₃ -C ₁₀ cycloalkyl containing 0-3 heteroatoms selected from O, S and N, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl containing 1-3 heteroatoms selected from O, N and S, C ₇ -C ₁₄ alkaryl, C ₇ -C ₂₄ aralkyl, C ₄ -C ₂₃ alkheteroaryl containing 1-3 heteroatoms selected from O, N and S, substituted up to pergaloid C ₁ -C ₁₀ alkyl, substituted up to pergaloid C ₃ -C ₁₀ cycloalkyl containing 0-3 heteroatoms selected from O, N and S substituted up to pergaloid nd C ₆ -C ₁₄ aryl substituted with up to perhalogen C ₃ -C ₁₃ heteroaryl containing 1-3 heteroatoms selected from O, N and S, up to perhalogen substituted C ₇ -C ₂₄ aralkyl, substituted C until perhalogen ₇ -C ₂₄ alkaryl and substituted up to the pergaloid C ₄ -C ₂₃ alkheteroaryl and each Z is independently selected from the group consisting of -CN, -CO ₂ R ⁷ , -C (O) R ⁷ , -C (O) NR ⁷ R ⁷ , -NO ₂ , -OR ⁷ , -SR ⁷ , -NR ⁷ R ⁷ , -NR ⁷ C (O) OR ⁷ , -NR ⁷ C (O) R ⁷ , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy groups, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkenoyl, C ₃ -C ₁₀ cycloalkyl containing 0-3 heteroatoms selected from O, N and S, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl containing 1-3 heteroatoms selected from O, N and S, C ₇ -C ₂₄ alkaryl, C ₇ -C ₂₄ aralkyl, C ₄ -C ₂₃ alkheteroaryl containing 1-3 heteroatoms selected from O, N and S, substituted C ₁ -C ₁₀ alkyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkenoyl substituted C ₃ -C ₁₀ cycloalkyl containing 0-3 heteroatoms selected from O, N and S, substituted C ₆ -C ₁₂ aryl, substituted C ₇ -C ₂₄ alkaryl, substituted C ₇ -C ₂₄ aralkyl and substituted C ₄ -C ₁₂ alkheteroaryl containing 1-3 heteroatoms selected from O , N and S; moreover, if Z is a substituted group, one or more substituents are selected from the group consisting of —CN, —CO ₂ R ⁷ , —COR ⁷ , —C (O) NR ⁷ R ⁷ , —OR ⁷ , —SR ⁷ , - NO ₂ , —NR ⁷ R ⁷ , —N ⁷ 7C (O) R ^7, and —NR ⁷ C (O) OR ⁷ . 3. The compound according to claim 1, characterized in that M represents one or more bridge groups selected from the group consisting of —O—, —S—, —N (R ⁷ ) -, - (CH ₂ ) _m - , -C (O) -, -CH (OH) -, - (СН ₂ ) _m О-, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁷ ) -, -O (СН ₂ ) _m - CHX ^a -, -CX ^a ₂ , -S- (CH ₂ ) _m - and -N (R ⁷ ) (CH ₂ ) _m -, where m = 1-3, X ^a is halogen, a R ^{7 is} defined in claim 1. 4. The compound according to claim 1, characterized in that the cyclic structures B and L, bonded directly to D, are not substituted in the ortho-position with OH hydroxyl. 5. The compound according to claim 1, characterized in that the cyclic structures B and L linked directly to D are not substituted in the ortho position by a structure containing ionizable hydrogen, and the pKa value is 10 or less. 6. The compound according to claim 1, characterized in that B in formula I is a substituted or unsubstituted six-membered aryl structure or six-membered hetaryl structure, wherein said heteroaryl structure containing 1-4 members is selected from the group of heteroaryl atoms consisting of nitrogen, oxygen and sulfur by balancing the heteroaryl structure with carbon. 7. The compound according to claim 1, characterized in that B in formula I is an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl group, a phenyl group substituted with a substituent selected from the group consisting of halogen and Wn, a pyrimidinyl group substituted with a substituent, selected from the group consisting of halogen and Wn, or substituted with a pyridyl group, substituted with a substituent selected from the group consisting of halogen and Wn. 8. The compound according to claim 6, characterized in that B in the formula I represents a substituted phenyl group, a substituted pyrimidinyl group or a substituted pyridyl group, substituted 1-3 times by 1 or more substituents selected from the group consisting of —CN, halogen , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy groups, -OH substituted until the formation of a pergaloid C ₁ -C ₁₀ alkyl, substituted until the formation of a pergaloid C ₁ -C ₁₀ alkoxy groups or phenyl substituted by a halogen until the formation of a pergaloid phenyl. 9. The compound according to claim 1, characterized in that the L-six-membered cyclic structure bound directly to D is a substituted or unsubstituted 6-membered heteroaryl structure, said heteroaryl structure having 1-4 members selected from the group of heteroatoms consisting from nitrogen, oxygen and sulfur while balancing said heteroaryl structure with carbon, where one or more substituents are selected from the group consisting of halogen and Wn. 10. The compound of claim 8, wherein L is a 6-membered cyclic structure linked directly by D and is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group. 11. The compound according to claim 1, characterized in that said substituted cyclic structure L ¹ contains a 5-6 membered aryl structure or heteroaryl structure, wherein said heteroaryl structure contains 1-4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur. 12. The compound according to claim 1, characterized in that said substituted cyclic structure of L ¹ is phenyl, pyridinyl or pyrimidinyl. 13. The compound according to claim 3, characterized in that said substituted cyclic structure of L ¹ is phenyl, pyridinyl or pyrimidinyl. 14. The compound according to claim 6, characterized in that said substituted cyclic structure of L ¹ is phenyl, pyridinyl or pyrimidinyl. 15. The compound of claim 8, wherein said substituted cyclic structure of L ¹ is phenyl, pyridinyl or pyrimidinyl. 16. The compound according to claim 9, characterized in that said substituted cyclic structure of L ¹ is phenyl, pyridinyl or pyrimidinyl. 17. The compound of claim 10, wherein said substituted cyclic structure of L ¹ is phenyl, pyridinyl or pyrimidinyl. 18. The compound according to 14, characterized in that M represents at least one bridge group selected from the group consisting of —O—, —S—, —N (R ⁷ ) -, - (CH ₂ ) _m -, -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁷ ) -, -O ( CH ₂ ) _m - CHX ^a -, -CX ^a ₂ , -S- (CH ₂ ) _m - and -N (R ⁷ ) (CH ₂ ) _m -, where m = 1-3, X ^a is halogen and R ⁷ is hydrogen or a carbon-based structure containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted with halogen until the formation of a pergaloid compound. 19. The compound according to clause 15, wherein M represents one or more bridge groups selected from the group consisting of —O—, —S—, —N (R ⁷ ) -, - (CH ₂ ) _m - , -C (O) -, -CH (OH) -, - (CH ₂ ) _m О-, - (CH ₂ ) _m , S-, - (CH ₂ ) _m N (R ⁷ ) -, -O ( CH ₂ ) _m -CHX ^a , -CX ^a ₂ , -S- (CH ₂ ) _m - and -N (R ⁷ ) (CH ₂ ) _m -, where m = 1-3, X ^a is halogen and R ⁷ - hydrogen or a carbon-based structure containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted with halogen until the formation of a perhaloid compound. 20. The compound according to clause 16, wherein M represents one or more bridge groups selected from the group consisting of —O—, —S—, —N (R ⁷ ) -, - (CH ₂ ) _m - , -C (O) -, -CH (OH) -, - (CH ₂ ) _m О-, - (CH ₂ ) _m .S-, - (CH ₂ ) _m N (R ⁷ ) -, -O ( CH ₂ ) _m - CHX ^a -, -CX ^a ₂ , -S- (CH ₂ ) _m - and -N (R ⁷ ) (CH ₂ ) _m -, where m = 1-3, X ^a is halogen and R ⁷ is hydrogen or a carbon-based structure containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted with halogen until the formation of a pergaloid compound. 21. The compound according to 17, characterized in that M represents one or more bridge groups selected from the group consisting of —O—, —S—, —N (R ⁷ ) -, - (CH ₂ ) _m - , -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁷ ) -, -O ( CH ₂ ) _m - CHX ^a -, -CX ^a ₂ , -S- (CH ₂ ) _m - and -N (R ⁷ ) (CH ₂ ) _m -, where m = 1-3, X ^a is halogen and R ⁷ is hydrogen or a carbon-based structure containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted with halogen until the formation of a pergaloid compound. 22. The compound according to claim 1, characterized in that L ^{1 is} additionally substituted 1-3 times with at least one substituent selected from the group consisting of C ₁ -C ₁₀ alkyl substituted with halogen until the formation of a pergaloid C ₁ -C ₁₀ alkyl, —CN, —OH, halogen, a C ₁ -C ₁₀ alkoxy group and substituted with a halogen until the formation of a perhaloid compound C ₁ -C ₁₀ alkoxy group. 23. The compound according to item 13, wherein L ^{1 is} additionally substituted 1-3 times by one or more substituents selected from the group consisting of C ₁ -C ₁₀ alkyl substituted with halogen until the formation of a pergaloid C ₁ -C ₁₀ alkyl , —CN, —OH, halogen, a C ₁ -C ₁₀ alkoxy group and substituted with a halogen until the formation of the perhaloid compound C ₁ -C ₁₀ alkoxy group. 24. The compound according to p. 18, characterized in that L ^{1 is} additionally substituted 1-3 times by one or more substituents selected from the group consisting of C ₁ -C ₁₀ alkyl substituted with halogen until the formation of a pergaloid C ₁ -C ₁₀ alkyl , —CN, —OH, halogen, C ₁ -C ₁₀ alkoxy groups and substituted with halogen until the formation of the perhaloid compound C ₁ -C ₁₀ alkoxy groups. 25. The compound according to claim 19, characterized in that L ^{1 is} additionally substituted 1-3 times by one or more substituents selected from the group consisting of C ₁ -C ₁₀ alkyl substituted with halogen until the formation of a pergaloid C ₁ -C ₁₀ alkyl , —CN, —OH, halogen, C ₁ -C ₁₀ alkoxy groups and substituted with halogen until the formation of the perhaloid compound C ₁ -C ₁₀ alkoxy groups. 26. The compound according to claim 20, characterized in that L ^{1 is} additionally substituted 1-3 times by one or more substituents selected from the group consisting of C ₁ -C ₁₀ alkyl substituted with halogen until the formation of a pergaloid C ₁ -C ₁₀ alkyl , —CN, —OH, halogen, C ₁ -C ₁₀ alkoxy groups and substituted with halogen until the formation of the perhaloid compound C ₁ -C ₁₀ alkoxy groups. 27. The compound according to item 21, wherein L ^{1 is} additionally substituted 1-3 times by one or more substituents selected from the group consisting of C ₁ -C ₁₀ alkyl substituted with halogen until the formation of a pergaloid C ₁ -C ₁₀ alkyl , —CN, —OH, halogen, a C ₁ -C ₁₀ alkoxy group and substituted with a halogen until the formation of the perhaloid compound C ₁ -C ₁₀ alkoxy group. 28. The compound according to claim 1, characterized in that L ^{1 is} substituted by —C (O) R _x . 29. The compound according to claim 1, characterized in that L ^{1 is} substituted by —SO ₂ R _x . 30. The compound according to claim 1, characterized in that L ^{1 is} substituted only by -C (O) R _x . 31. The compound according to claim 1, characterized in that L ^{1 is} substituted only by -SO ₂ R _x . 32. The compound according to claim 1, characterized in that L ^{1 is} substituted by —C (O) R _x or —SO ₂ R _x , where R _x is NR _a R _b . 33. The compound according to item 13, wherein L ^{1 is} substituted by —C (O) R _x or —SO ₂ R _x , where R _x is NR _a R _b and R _a and R _b are a) independently by hydrogen, a carbon-based structure containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted with halogen, hydroxy and carbon-based substituents containing up to 24 carbon atoms, which optionally contain heteroatoms, selected from N, S and O, and optionally substituted with halogen, or -OSi (R _f ) ₃ , where R _f is hydrogen or a carbon-based structure containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O , and optionally deputy ester with halogen, hydroxy and carbon-based substituents containing up to 24 carbon atoms, which optionally contains heteroatoms selected from N, S and O, and optionally substituted with halogen, or b) R _a and R _b together form a 5-7 membered heterocyclic a structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7-membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O, substituted by a halogen, hydroxy group or carbon-based substituents containing up to 24 carbon atoms that optionally contain RAT heteroatoms selected from N, S and O, optionally substituted with halogen, or c) one of R _a or R _b is -C (O) -, C ₁ -C ₅ divalent alkylene group or a substituted C ₁ -C ₅ divalent an alkylene group bonded to structure L to form a cyclic structure of at least 5 members in which substituents of a substituted C ₁ -C ₅ divalent alkylene group are selected from the group consisting of halogen, a hydroxy group and carbon-based substituents containing up to 10-24 carbon atoms that optionally contain goethe oatomy selected from N, S and O and are optionally substituted by halogen. 34. The compound according to p. 18, wherein L ^{1 is} substituted by —C (O) R _x or —SO ₂ R _x , where R _x is NR _a R _b , and R _a and R _{b are} independently hydrogen or a structure on a carbon base containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted with a halogen, hydroxy group and carbon-based substituents containing up to 24 carbon atoms, which optionally contains heteroatoms selected from N, S and Oh, and is optionally substituted with halogen. 35. The compound according to claim 19, wherein L ¹ is substituted by —C (O) R _x , where R _x is NR _a R _b , and R _a and R _{b are} independently hydrogen or a carbon-based structure containing up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted with halogen, hydroxy and carbon-based substituents containing up to 24 carbon atoms that optionally contain heteroatoms selected from N, S and O, and are optionally substituted by halogen. 36. The compound according to claim 20, wherein L ¹ is substituted by —C (O) R _x or —SC ₂ R _x , where R _x is NR _a R _b , and R _a and R _{b are} independently hydrogen or a structure based on carbon containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted with halogen, hydroxy and carbon-based substituents containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, and are optionally substituted with halogen. 37. The compound according to item 21, wherein L ¹ is substituted by —C (O) R _x or —SC ₂ R _x , where R _x is NR _a R _b , and R _a and R _{b are} independently hydrogen or a structure based on carbon containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted with halogen, hydroxy and carbon-based substituents containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, and are optionally substituted with halogen. 38. The compound of the General formula A-D-B (I) or a pharmaceutically acceptable salt thereof, where D is —NH — C (O) —NH—; A is a substituted structure containing up to 40 carbon atoms of the formula: -L- (ML ¹ ) q, where L is a 6-membered aryl structure or a 6-membered heteroaryl structure linked directly to D, L ¹ contains a substituted cyclic structure containing at least 5 members, M is a bridging group containing at least one atom, q is a whole a number from 1 to 3 and each cyclic structure of L and L ¹ contains 0-4 members of a group consisting of nitrogen, oxygen and sulfur, and B is substituted or unsubstituted up to a tricyclic aryl or heteroaryl structure containing up to 30 carbon atoms with at least Leray one 6-membered cyclic structure bound directly to D, containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein L ¹ is substituted by at least one substituent selected from the group consisting of -SO ₂ R _x , —C (O) R _x and —C (NR _y ) R _z , R _y is hydrogen or a carbon-based structure containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally halogen-substituted perhalogen compounds, R _z - hydrogen or a carbon based structure containing up to 30 carbon atoms, neobyaza tionary containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents on containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and optionally substituted by halogen; R _x is R _z or NR _a R _b , wherein R _a and R _b a) are independently represented by hydrogen, a carbon-based structure containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted with halogen , hydroxy group and carbon-based substituents containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, and are optionally substituted with halogen, or —OSi (R _f ) ₃ , where R _f is hydrogen or a structure based carbon containing up to 24 carbon atoms, optionally containing g heteroatoms selected from N, S, and O, and optionally substituted with halogen, hydroxy, and carbon-based substituents containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S, and O, and optionally substituted with halogen, or b) R _a and R _b locally form a 5-7 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O, substituted with halogen, hydroxy or carbon-based substituents containing and up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, optionally substituted with halogen, or c) one of R _a or R _b, represents -C (O) -, C ₁ -C ₅ divalent alkylene a group or substituted C ₁ -C ₅ divalent alkylene group bonded to structure L to form a cyclic structure of at least 5 members, in which substituents of the substituted C ₁ -C ₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy group and substituents based on carbon containing up to 24 atom carbon, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; where B is substituted, L is substituted or L ¹ is further substituted, wherein the substituents are selected from the group consisting of halogen up to the perhaloid compound and Wn, where n = 0-3; each W independently selected from the group consisting of —CN, —CO ₂ R ⁷ , —C (O) NR ⁷ R ⁷ , —C (O) —R ⁷ , —NO ₂ , —OR ⁷ , —SR ⁷ , -NR ⁷ R ⁷ , -NR ⁷ C (O) OR ⁷ , -NR ⁷ C (O) R ⁷ , -Q-Ar and carbon-based structures containing up to 24 carbon atoms, optionally containing heteroatoms selected from N , S and O, and optionally substituted with one or more substituents independently selected from the group consisting of CN, —CO ₂ R ⁷ , —C (O) NR ⁷ R ⁷ , —C (O) —R ⁷ , —NO ₂ , -OR ⁷ , -SR ⁷ , -NR ⁷ R ⁷ , -NR ⁷ C (O) OR ⁷ , -NR ⁷ C (O) R ⁷ and halogen up to the perhaloid compound, with each R ⁷ independently selected from H or carbon based structures containing boiling up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is —O—, —S—, —N (R ⁷ ) -, - (CH ₂ ) _m -, —C (O) -, —CH (OH) -, - (CH ₂ ) _m O— , - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁷ ) -, -O (CH ₂ ) _m - CHX ^a -, -CX ^a ₂ , -S- (CH ₂ ) _m - and —N (R ⁷ ) (CH ₂ ) _m -, where m = 1-3, and X ^a is halogen, Ar is a 5- or 6-membered aromatic structure containing 0-2 members selected from the group consisting of from nitrogen, oxygen and sulfur, which is optionally substituted with halogen up to the pergaloid compound and optionally substituted with Z _n1 , where n1 = 0-3 and each Z is independently selected from the group consisting of -CN, -CO ₂ R ⁷ , -C ( O) NR ⁷ R ⁷ , -C (O) R ⁷ , -NO ₂ , -OR ⁷ , -SR ⁷ , -NR ⁷ R ⁷ , -NR ⁷ C (O) OR ⁷ , -NR ⁷ C (O) R ⁷ and carbon-based structures containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted with one or more substituents selected from the group consisting of —CN, —CO ₂ R ⁷ , —C (O) NR ⁷ R ⁷ , -C (O) R ⁷ , -NO ₂ , -OR ⁷ , -SR ⁷ , -NR ⁷ R ⁷ , -NR ⁷ C (O) OR ⁷ , -NR ⁷ C (O ) R ⁷ , where R ^{7 is} defined above, and where M is at least one bridge group selected from the group consisting of —O—, —S—, —N (R ⁷ ) -, - (CH ₂ ) _m - , -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, - (CH ₂ ) _m S- - (CH ₂ ) _m N (R ⁷ ) -, -O (CH ₂ ) _m is CHX ^a -, -CX ^a ₂ , -S- (CH ₂ ) _m - and -N (R ⁷ ) (CH ₂ ) _m -, where m = 1-3, X ^a is halogen. 39. The compound of the General formula A-D-B (I) or a pharmaceutically acceptable salt thereof, where D is —NH — C (O) —NH—; A is a substituted structure containing up to 40 carbon atoms of the formula: -L- (ML ¹ ) _q , where L is a substituted or unsubstituted phenyl or pyrynyl structure bonded directly to D, L ¹ contains a substituted phenyl, pyridinyl or pyrimidinyl structure, M is a bridging group containing at least one atom, q is an integer from 1 to 3, and B is a substituted or unsubstituted phenyl or pyridine group bonded directly to D, wherein L ¹ is substituted with at least one substituent selected from the group consisting of —SO ₂ R _x , —C (O) R _x and —C (NR _y ) R _z , R _y is hydrogen or a carbon-based structure, containing up to 24 carbon atoms, optionally containing heteroatoms selected from N, S, and O, and optionally halogen-substituted up to a perhaloid compound, R _z is hydrogen or a carbon-based structure containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted with halogen, hydroxy and substituents on the main carbon ova containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, and are optionally substituted with halogen; R _x is R _z or NR _a R _b , where R _a and R _b a) are independently hydrogen, a carbon-based structure containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted with halogen , hydroxy group and carbon-based substituents containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, and are optionally substituted with halogen, or —OSi (R _f ) ₃ , where R _f is hydrogen or a structure based carbon containing up to 24 carbon atoms, optionally containing goethe oatomy selected from N, S and O and optionally substituted by halogen, a hydroxy group, and substituents on the carbon basis, containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and optionally substituted by halogen, or b) R _a and R _b together form a 5-7 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 membered heterocyclic structure of 1-3 heteroatoms selected from N, S and O, substituted with halogen, hydroxy or carbon-based substituents containing about 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, optionally substituted with halogen, or c) one of R _a or R _b is -C (O) -, C ₁ -C ₅ divalent alkylene group or a substituted C ₁ -C ₅ divalent alkylene group bonded to structure L to form a cyclic structure of at least 5 members in which substituents of the substituted C ₁ -C ₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy group and substituents based on carbon containing up to 24 carbon atoms hydrocarbons which optionally contain heteroatoms selected from N, S and O, and are optionally substituted with halogen; where B is substituted, L is substituted or L ¹ is further substituted, wherein the substituents are selected from the group consisting of halogen up to the perhaloid compound and Wn, where n = 0-3; each W independently selected from the group consisting of —CN, —CO ₂ R ⁷ , —C (O) NR ⁷ R ⁷ , —C (O) —R ⁷ , —NO ₂ , —OR ⁷ , —SR ⁷ , -NR ⁷ R ⁷ , -NR ⁷ C (O) OR ⁷ , -NR ⁷ C (O) R ⁷ , -Q-Ar and carbon-based structures containing up to 24 carbon atoms, optionally containing heteroatoms selected from N , S and O, and optionally substituted with at least one substituent independently selected from the group consisting of —CN, —CO ₂ R ⁷ , —C (O) R ⁷ , —C (O) NR ⁷ R ⁷ , —OR ⁷ , -C (O) -R ⁷ , -OR ⁷ , -SR ⁷ , -NR ⁷ R ⁷ , -NO ₂ , -NR ⁷ C (O) OR ⁷ , -NR ⁷ C (O) R ⁷ and halogen until the formation of perhalogen compounds despite the fact that each of R ⁷ is independently selected from H or strukt ry based on carbon containing up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is -O-, -S-, -N (R ⁷⁾ -, - ( CH ₂ ) _m -, -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁷ ) - , -O (CH ₂ ) _m - CHX ^a -, -CX ^a ₂ , -S- (CH ₂ ) _m - and -N (R ⁷ ) (CH ₂ ) _m -, where m = 1-3, X ^a - halogen, Ar is a 5- or 6-membered aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted with halogen until the formation of a perhaloid compound and not byazatelno substituted by Z _n1 where n1 = 0-3 and each Z is independently selected from the group consisting of -CN, -CO ₂ R ^7, -C (O) R ^7, -C (O) NR ⁷ R ^7, -NO ₂ , —OR ⁷ , —SR ⁷ , —NR ⁷ R ⁷ , —NR ⁷ C (O) OR ⁷ , —NR ⁷ C (O) R ^7, and carbon-based structures containing up to 24 carbon atoms, optionally containing heteroatoms, selected from N, S and O, and optionally substituted with one or more substituents selected from the group consisting of —CN, —CO ₂ R ⁷ , —C (O) R ⁷ , —C (O) NR ⁷ R ⁷ , - NO ₂ , -OR ⁷ , -SR ⁷ , -NR ⁷ R ⁷ , -NR ⁷ C (O) OR ⁷ , -NR ⁷ C (O) R ⁷ and where M is one or more bridge groups selected from the group, consisting of -O-, -S-, -N (R ⁷ ) -, - (CH ₂ ) _m -, -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, - (CH ₂ ) _m S- , - (CH _{2) m} N (R ⁷⁾ -, -O (CH _{2) m} - CHX ^a -, -CX ^a _2, -S- (CH _{2) m} - and -N (R ₇₎ (CH ₂ ) _m -, where m = 1-3, X ^a is halogen. 40. The compound according to § 38, wherein the cyclic structures B and L linked directly to D are unsubstituted -OH in the ortho position. 41. The compound according to claim 38, wherein the cyclic structures B and L directly bonded to D are an unsubstituted ortho-position structure having an ionizable hydrogen atom, and the pKa value is 10 or less. 42. The compound according to § 39, wherein the cyclic structures B and L directly bonded to D are unsubstituted -OH in the ortho position. 43. The compound according to § 39, wherein the cyclic structures B and L linked directly to D are an unsubstituted ortho position structure having an ionizable hydrogen atom, and the pKa value is 10 or less. 44. The compound according to § 38, wherein the substituents for B and L and additional substituents for L ¹ are selected from the group consisting of C ₁ -C ₁₀ alkyl up to a perhalo-substituted C ₁ -C ₁₀ alkyl, CN, OH , halogen, C ₁ -C ₁₀ alkoxy groups and up to the perhalo-substituted C ₁ -C ₁₀ alkoxy group. 45. The compound according to § 39, wherein the substituents for B and L and additional substituents for L ¹ are selected from the group consisting of C ₁ -C ₁₀ alkyl up to a perhalo-substituted C ₁ -C ₁₀ alkyl, CN, OH , halogen, C ₁ -C ₁₀ alkoxy groups and up to the perhalo-substituted C ₁ -C ₁₀ alkoxy group. 46. The compound of claim 38, wherein L ¹ is substituted with C (O) R _x or SO ₂ R _x . 47. The compound according to § 39, wherein L ¹ is substituted with C (O) R _x or SO ₂ R _x . 48. The compound of claim 46, wherein R _x is NR _a R _b and R _a and R _{b are} independently hydrogen and a carbon-based structure containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S, and O, and optionally substituted with halogen, hydroxy, and carbon-based substituents containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S, and O, and are optionally substituted with halogen. 49. The compound of claim 47, wherein R _x is NR _a R _b and R _a and R _{b are} independently hydrogen and a carbon-based structure containing up to 30 carbon atoms, optionally containing heteroatoms selected from N, S, and O, and optionally substituted with halogen, hydroxy, and carbon-based substituents containing up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S, and O, and are optionally substituted with halogen. 50. The compound according to claim 1, characterized in that it is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of a)     basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid (tosylate salt), 1-naphthalenesulfonic acid -naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid slots of maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid, and b) salts of acids of organic and inorganic bases containing cations selected from the group consisting of alkali metal cations, alkaline earth metal cations, ammonium cation, aliphatic substituted cations ammonium and aromatic substituted ammonium cations. 51. The compound according to claim 2, characterized in that it is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid (tosylate salt), 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid, and b) salts of acids of organic and inorganic bases containing cations selected from the group consisting of alkali metal cations, alkaline earth metal cations, ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations he and I. 52. The compound according to p. 33, characterized in that it is a pharmaceutically acceptable salt of the compounds of formula I, selected from the group consisting of a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid (tosylate salt), 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid, and b) organic and inorganic acid salts bases containing cations selected from the group consisting of alkali metal cations, alkaline earth metal cations, ammonium cation, aliphatic substituted ammonium cations and aromatic substituted amine cations monia. 53. The compound of claim 38, wherein it is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid (tosylate salt), 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid, and b) organic and inorganic acid salts bases containing cations selected from the group consisting of alkali metal cations, alkaline earth metal cations, ammonium cation, aliphatic substituted ammonium cations and aromatic substituted amine cations monia. 54. The compound according to § 39, characterized in that it is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid (tosylate salt), 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid, and b) organic and inorganic acid salts bases containing cations selected from the group consisting of alkali metal cations, alkaline earth metal cations, ammonium cation, aliphatic substituted ammonium cations and aromatic substituted amine cations Onias. 55. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt of a compound of formula I and a physiologically acceptable carrier. 56. A pharmaceutical composition comprising a compound according to claim 2, corresponding to formula I, or a pharmaceutically acceptable salt thereof and a physiologically acceptable carrier. 57. A pharmaceutical composition comprising a compound according to claim 33, corresponding to Formula I, or a pharmaceutically acceptable salt thereof and a physiologically acceptable carrier. 58. A pharmaceutical composition comprising a compound of claim 38, corresponding to Formula I, or a pharmaceutically acceptable salt thereof and a physiologically acceptable carrier. 59. A pharmaceutical composition comprising a compound according to claim 39, corresponding to Formula I, or a pharmaceutically acceptable salt thereof and a physiologically acceptable carrier. 60. A compound selected from the group consisting of 3-tert-butylphenylureas shown in table 1; 5-tert-butyl-2-methoxyphenylureas shown in table 2; 5- (trifluoromethyl) -2-phenylurea shown in table 3; 3- (trifluoromethyl) -4-chlorophenylureas shown in table 4; 3- (trifluoromethyl) -4-bromophenylureas shown in table 5; 5- (trifluoromethyl) -4-chloro-2-methoxyphenylureas shown in Table 6; and urea are presented in table 7 under the numbers 101-103. 61. A compound selected from the group consisting of 3-tert-butylphenylurea: N- (3-tert-butylphenyl) -N ’- (4- (3- (N-methylcarbamoyl) phenoxy) phenylurea and N (3-tert-butylphenyl) -N ’- (4- (4-acetylphenoxy) phenylurea; 5-tert-butyl-2-methoxyphenylurea: N- (5-tert-butyl-2-methoxyphenyl) -N '- (4- (1,3-dioxoisoindolin-5-yloxy) phenyl) urea, N- (5-tert-butyl-2-methoxyphenyl) -N '- (1-oxoisoindolin-5-yloxy) phenyl) urea, N- (5-tert-butyl-2-methoxyphenyl) -N '- (4- (4-methoxy-3- (N-methylcarbamoyl) phenoxy) phenyl) urea and N- (5-tert-butyl-2-methoxyphenyl) -N '- (4- (3- (N-methylcarbamoyl) phenoxy) phenyl) urea; 2-methoxy-5- (trifluoromethyl) phenylurea: N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (4- (2- (M-methylcarbamoyl) -4-pyridylthio) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (2-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea and N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (3-chloro-4- (2- (N'-methylcarbamoyl) - (4-pyridyloxy)) phenyl) urea; 4-chloro-3- (trifluoromethyl) phenyl urea: N- (4-chloro-3- (trifluoromethyl) phenyl-N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (2- (M-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) urea and N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea; 4-bromo-3- (trifluoromethyl) phenylurea: N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridylthio) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (2-chloro-4- (2- (N-methylcarbamoyl) - (4-pyridyloxy)) phenyl) urea and N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea and 2-methoxy-4-chloro-5- (trifluoromethyl) phenylurea: N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N '- (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N '- (2-chloro-4- (2- (N-methyl-carbamoyl) (4-pyridyloxy)) phenyl) urea and N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N '- (3-chloro-4- (2- (N-methyl-carbamoyl) (4-pyridyloxy)) phenyl) urea. 62. A method of treating a disease associated with the growth of cancer cells mediated by raf kinase, comprising administering a compound of formula I according to claim 1. 63. A method of treating a disease associated with the growth of cancer cells mediated by raf kinase, comprising administering a compound of formula I according to claim 33. 64. A method of treating a disease associated with the growth of cancer cells mediated by raf kinase, comprising administering a compound of formula I according to claim 38. 65. A method of treating a disease associated with the growth of cancer cells mediated by raf kinase, comprising administering a compound of formula I according to claim 39. 66. A method of treating a disease associated with the growth of cancer cells mediated by raf kinase, comprising administering a compound selected from the group consisting of 3-tert-butylphenylureas shown in Table 1; 5-tert-butyl-2-methoxyphenylureas shown in table 2; 5- (trifluoromethyl) -2-phenylurea shown in table 3; 3- (trifluoromethyl) -4-chlorophenylureas shown in table 4; 3- (trifluoromethyl) -4-bromophenylureas shown in table 5; 5- (trifluoromethyl) -4-chloro-2 methoxyphenylureas shown in table 6; and urea, are presented in table 7, under the numbers 101-103. 67. A method of treating a disease associated with the growth of cancer cells mediated by raf kinase, comprising administering a compound selected from the group consisting of 3-tert-butylphenylureas: N- (3-tert-butylphenyl) -N '- (4- (3- (N-methylcarbamoyl) phenoxy) phenylurea and N- (3-tert-butylphenyl) -N '- (4- (4-acetylphenoxy) phenyl urea; 5-tert-butyl-2-methoxyphenylurea: N- (5-tert-butyl-2-methoxyphenyl) -N '- (4- (1,3-dioxoisoindolin-5-yloxy) phenyl) urea, N- (5-tert-butyl-2-methoxyphenyl) -N '- (1-oxoisoindolin-5-yloxy) phenyl) urea, N- (5-tert-butyl-methoxyphenyl) -N '- (4- (4-methoxy-3- (N-methylcarbamoyl) phenoxy) phenyl) urea and N- (5-tert-butyl-2-methoxyphenyl) -N '- (4- (3- (N-methylcarbamoyl) phenoxy) phenyl) urea; 2-methoxy-5- (trifluoromethyl) phenylurea: N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (4- (2- (N-methylcarbamoyl) -4-pyridylthio) phenyl) urea, N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (2-chloro-4- (2- (N-methylcarbamoyl) - (4-pyridyloxy)) phenyl) urea and N- (2-methoxy-5- (trifluoromethyl) phenyl) -N '- (3-chloro-4- (2- (N'-methylcarbamoyl) - (4-pyridyloxy)) phenyl) urea; 4-chloro-3- (trifluoromethyl) phenylurea: N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) urea and N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea; 4-bromo-3- (trifluoromethyl) phenyl urea: N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridylthio) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (2-chloro-4- (2- (N-methylcarbamoyl) - (4-pyridyloxy)) phenyl) urea and N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3-chloro-4- (2- (N-methylcarbamoyl) - (4-pyridyloxy)) phenyl) urea and 2-methoxy-4- chloro-5- (trifluoromethyl) phenylurea: N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N '- (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N '- (2-chloro-4- (2- (N-methyl-carbamoyl) (4-pyridyloxy)) phenyl) urea and N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N '- (3-chloro-4- (2- (N-methyl-carbamoyl) (4-pyridyloxy)) phenyl) urea.